Lower beta cell function relates to sustained higher glycated albumin to glycated hemoglobin ratio in Japanese patients with type 2 diabetes

We recently reported that glycated albumin (GA) is increased in subjects with longer duration of diabetes and with decreased insulin secretory function. Based on this, we investigated whether GA increases with time relative to glycated hemoglobin (HbA1c) and the association between GA and beta-cell function. We analyzed 340 type 2 diabetes patients whose serum GA and HbA1c levels had been repeatedly measured over 4 years. We assessed the pattern of changes with time in glycemic indices (GA,HbA1c, and GA/HbA1cratio) and their relationship with beta-cell function. In all patients, glycemic indices decreased and maintained low levels around 15 and 27 months. However, from 39 months to 51 months, GA significantly increased butHbA1ctended to increase without statistical significance. We defined ΔGA/HbA1cas the difference between the nadir point (at 15 to 27 months) and the end point (at 39 to 51 months) and found that ΔGA/HbA1cwas positively correlated with diabetes duration and negatively related to beta-cell function. In multivariable linear regression analyses, ΔGA/HbA1cwas independently associated with diabetes duration. In conclusion, this study demonstrated that serum GA levels increase relative toHbA1clevels with time.

Download Full-text

The Postprandial C-peptide–to–Glucose Ratio Correlated with Beta-Cell Function in Japanese Patients with Type 2 Diabetes Mellitus

Diabetes ◽

10.2337/db18-1831-p ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 1831-P

Author(s):

YUKI MATSUHASHI ◽

SHINJI CHIKAZAWA ◽

HIROFUMI NAKAYAMA ◽

MASAYA MURABAYASHI ◽

SATORU MIZUSHIRI ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Beta Cell ◽

Beta Cell Function ◽

Cell Function ◽

Japanese Patients ◽

C Peptide ◽

Glucose Ratio

Download Full-text

Correlation Between Glycated Hemoglobin and Homa Indices in Type 2 Diabetes Mellitus: Prediction of Beta-Cell Function from Glycated Hemoglobin / Korelacija Između Glikoliziranog Hemoglobina I Homa Indeksa U Dijabetes Melitusu Tipa 2: Predviđanje Funkcije Beta Ćelija Na Osnovu Glikoliziranog Hemoglobina

Journal of Medical Biochemistry ◽

10.2478/jomb-2014-0033 ◽

2015 ◽

Vol 34 (2) ◽

pp. 191-199 ◽

Cited By ~ 6

Author(s):

Hussein Kadhem Al-Hakeim ◽

Mohammed Saied Abdulzahra

Keyword(s):

Diabetes Mellitus ◽

Insulin Resistance ◽

Type 2 Diabetes ◽

Beta Cell ◽

Beta Cell Function ◽

Cell Function ◽

Glycated Hemoglobin ◽

Control Groups ◽

Poor Control

Summary Background: The present study aimed to determine the most efficient insulin resistance function related to gly - cemic control expressed as glycated hemoglobin (HbA1c) in type 2 diabetes mellitus patients (T2DM). The other aim is to derive equations for the prediction of beta cell functions containing HbA1c as a parameter in addition to fasting glucose and insulin. Methods: T2DM Patients were grouped according to the following: (1) degree of control (good, fair, and poor control) and (2) insulin resistance as observed in obtained data and significant differences revealed by the homeostasis model assessment (HOMA) of related parameters (insulin resistance = HOMA2IR, beta-cell function = HOMA%B, and in sulin sensitivity = HOMA%S) among groups. Corre - lations and forecasting regression analysis were calculated. Results: HbA1c was found to be correlated with insulin resistance parameters in T2DM subgroups. This correlation was also significantly correlated with HOMA%B and the quantitative insulin sensitivity check index (QUICKI) in fair and poor control groups. Regression analysis was used to predict the forecasting equations for HOMA%B. The best applicable equations were derived for healthy control (HOMA2%B=-1.76*FBG+5.00*Insulin+4.69*HbA1c+189.84) and poor control groups (HOMA2%B=0.001* FBG+0.5*Insulin-8.67*HbA1c+101.96). These equations could be used to predict b-cell function (HOMA%B) after FBG, insulin and HbA1c values were obtained for healthy and poor control groups. In the good and fair control groups, the applicability of the HOMA model fails to yield appropriate results. Conclusions: Beta-cell function is correlated with QUICKI and HbA1c and could be predicted properly from HbA1c, insulin, and glucose in the healthy and poor control groups. New regression equations were established that involve HbA1c.

Download Full-text

Blood intact incretin levels are related to beta-cell function and glycemia in patients with type 2 diabetes

Endocrine Abstracts ◽

10.1530/endoabs.63.gp201 ◽

2019 ◽

Author(s):

Yeekyoung Ko ◽

Soyeon Yoo ◽

Gwanpyo Koh

Keyword(s):

Type 2 Diabetes ◽

Beta Cell ◽

Beta Cell Function ◽

Cell Function

Download Full-text

78-OR: Glycaemia, Beta-Cell Function, and Incretin Hormones Post-OGTT One Year after Gastric Bypass and Sleeve Gastrectomy in Patients with Morbid Obesity and Type 2 Diabetes: An RCT (Oseberg Study)

Diabetes ◽

10.2337/db20-78-or ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 78-OR

Author(s):

FARHAT FATIMA ◽

JØRAN HJELMESÆTH ◽

KARE I. BIRKELAND ◽

HANNE L. GULSETH ◽

JENS K. HERTEL ◽

...

Keyword(s):

Type 2 Diabetes ◽

Morbid Obesity ◽

Gastric Bypass ◽

Sleeve Gastrectomy ◽

Beta Cell ◽

Beta Cell Function ◽

Cell Function ◽

Incretin Hormones ◽

One Year

Download Full-text

Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study

BMJ Open Diabetes Research & Care ◽

10.1136/bmjdrc-2021-002208 ◽

2021 ◽

Vol 9 (1) ◽

pp. e002208

Author(s):

Marcus Hompesch ◽

Jahoon Kang ◽

OakPil Han ◽

Michael E Trautmann ◽

Christopher H Sorli ◽

...

Keyword(s):

Type 2 Diabetes ◽

Gastric Emptying ◽

Glucose Metabolism ◽

Beta Cell ◽

Beta Cell Function ◽

Cell Function ◽

Phase Ib ◽

Link Type ◽

Drug Concentrations

IntroductionTo evaluate the effects of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), on gastric emptying, glucose metabolism, and islet beta-cell function versus liraglutide and placebo in people with type 2 diabetes.Research design and methodsThis phase Ib study (ClinicalTrials.gov identifier: NCT02059564) randomized participants (n=47) to three cohorts. Within the first two cohorts, participants were randomized to placebo, efpeglenatide 6 mg weekly (QW; first cohort), or efpeglenatide 16 mg monthly (QM; second cohort). The third cohort received liraglutide 1.8 mg daily (QD). Gastric emptying was assessed through the pharmacokinetic (PK) profile of acetaminophen at baseline and steady state. Glucose metabolism and beta-cell function were assessed based on mixed-meal tolerance testing and a graded glucose infusion procedure.ResultsTreatment duration was approximately 3 months for efpeglenatide 16 mg QM and 1 month for efpeglenatide 6 mg QW and liraglutide. At peak drug concentrations, efpeglenatide 6 mg QW was non-inferior to liraglutide 1.8 mg QD in delaying gastric emptying, as assessed by acetaminophen PK (lower bound of 90% CI for the efpeglenatide:liraglutide ratio >0.8 for area under the curve (AUC)0–120, AUC0–180, AUC0–360 and maximum concentration (Cmax)). Efpeglenatide 16 mg QM did not decrease the rate of gastric emptying to as great an extent as liraglutide (ie, non-inferiority was not shown). Compared with liraglutide, both efpeglenatide dosing regimens demonstrated comparable or more favorable glucometabolic effects and improved beta-cell function. All gastrointestinal adverse events reported with efpeglenatide were mild or moderate in severity and transient over treatment and follow-up.ConclusionsThe glucometabolic effects of efpeglenatide 6 mg QW and 16 mg QM were comparable to liraglutide. Additional studies are necessary to further examine these benefits of efpeglenatide.Trial registration numberNCT02059564.

Download Full-text